On the morning of October 13,2021, our school and Sino-Swed Tongkang Biotech (Shenzhen) Co., Ltd. held the signing ceremony of the internship base in Conference Room 345 of the main building of Beijing Institute of Technology. SSTB Chairman Zhou Ji, co-President Xiao ChangXin, and secretary professor YanZhijun, professor li Jinlin, etc.  attended the signing ceremony.The signing ceremony was hosted by Professor Cui Lixin.

At the signing ceremony, after watching the promotional videos of the School of Management and Economics and Sino-Swede Tongkang Biotech (Shenzhen) Co., Ltd., Secretary Yan Zhijun first introduced the development of Beijing Institute of Technology and the School of Management and Economics and his hope for the construction of the internship base.Secretary Yan hopes that through the establishment of this internship base, it will provide a more down-to-earth platform for scientific research, teaching, internship practice, innovation and entrepreneurship for the teachers and students of the school, exercise and improve the innovation and practice ability of the teachers and students, and better meet the actual needs of the country and the society.

After that, Chairman Zhou Ji and Secretary Yan Zhijun signed the Agreement on behalf of both sides and completed the listing ceremony.

The School of Management and Economics of Beijing Institute of Technology, together with SSTK has successfully signed an internship base, opening a new chapter of school-enterprise cooperation and the integration of industry, university and research. While serving the society and enterprises, it has explored a new model of talent training.

Sino-Swede Tongkang Biotech (Shenzhen) Co., Ltd. was established on August 05,2002. It is an innovative national high-tech enterprise carrying the medical values of Sweden. Since its establishment, SSTK has been focused on cell proliferation marker thymidine kinase 1 (TK1) series of product research and development. Adhering to the "scientific human dedication", SSTK has successfully realized the laboratory major cutting-edge scientific research transformation in clinical practice, developed the world's first approved clinical application of serum TK1 test kit, take the lead in cell proliferation and cell cycle theory to tumor early risk warning system construction practice.